Daneng Li
Impact in
- Hepatology top 0.05%
- Hepatocellular Carcinoma Treatment and Prognosis
- Geriatrics and Gerontology top 0.5%
- Frailty in Older Adults
Papers in
- Hepatology 23
- Hepatocellular Carcinoma Treatment and Prognosis 23
-
- Frailty in Older Adults 17
- Co-authors
- Arti Hurria (8 shared papers)Enrique Soto‐Pérez‐de‐Celis (8 shared papers)Wendy J. Verret (4 shared papers)Masatoshi Kudo (4 shared papers)Alan Nicholas (3 shared papers)Philippe Merle (4 shared papers)Richard S. Finn (4 shared papers)Michel Pierre Ducreux (3 shared papers)
- Journals
- Journal of Geriatric Oncology (11 papers)Cancers (9 papers)The Lancet Oncology (6 papers)The Oncologist (5 papers)Breast Cancer Research and Treatment (3 papers)
- Partner nations
- United StatesChinaMexico
In The Last Decade
Daneng Li
100 papers receiving 12.6k citations
Daneng Li's Hit Papers
Peers
Comparison fields: 5 of 106
- Hepatology 7.2k
- Geriatrics and Gerontology 639
- Oncology 3.2k
- Cancer Research 437
- Surgery 775
Countries citing papers authored by Daneng Li
This map shows the geographic impact of Daneng Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daneng Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daneng Li more than expected).
Fields of papers citing papers by Daneng Li
This network shows the impact of papers produced by Daneng Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daneng Li. The network helps show where Daneng Li may publish in the future.
Co-authors
The 25 scholars most cited alongside Daneng Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 110 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma Hit paper breakdown → | 2020 | 5593 |
| 2 | Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial Hit paper breakdown → | 2018 | 2094 |
| 3 | Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma Hit paper breakdown → | 2021 | 1262 |
| 4 | Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial Hit paper breakdown → | 2023 | 374 |
| 5 | A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer Hit paper breakdown → | 2020 | 356 |
| 6 | Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial Hit paper breakdown → | 2023 | 326 |
| 7 | Geriatric Assessment–Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer Hit paper breakdown → | 2021 | 320 |
| 8 | 2018 | 300 | |
| 9 | Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial Hit paper breakdown → | 2021 | 293 |
| 10 | Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study Hit paper breakdown → | 2023 | 190 |
| 11 | 2007 | 125 | |
| 12 | 2009 | 113 | |
| 13 | 2021 | 83 | |
| 14 | 2019 | 75 | |
| 15 | 2020 | 69 | |
| 16 | 2019 | 67 | |
| 17 | 2018 | 57 | |
| 18 | 2021 | 49 | |
| 19 | Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b–2, study Hit paper breakdown → | 2025 | 48 |
| 20 | 2018 | 35 |
About Daneng Li
Daneng Li is a scholar working on Hepatology, Geriatrics and Gerontology, Oncology, Epidemiology and Surgery, having authored 110 papers that have together received 12.8k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (23 papers), Neuroendocrine Tumor Research Advances (18 papers), Frailty in Older Adults (17 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (14 papers), Cancer-related cognitive impairment studies (7 papers), Pancreatic and Hepatic Oncology Research (5 papers), Cancer survivorship and care (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). The work is most often cited by research in Hepatology (7.2k citations), Geriatrics and Gerontology (639 citations), Oncology (3.2k citations), Cancer Research (437 citations) and Surgery (775 citations). Daneng Li has collaborated with scholars based in United States, China and Mexico. Frequent co-authors include Arti Hurria, Enrique Soto‐Pérez‐de‐Celis, Wendy J. Verret, Masatoshi Kudo, Alan Nicholas, Philippe Merle, Richard S. Finn, Michel Pierre Ducreux, Ann‐Lii Cheng and Valeriy Vladimirovich Breder. Their work appears in journals such as Journal of Geriatric Oncology, Cancers, The Lancet Oncology, The Oncologist and Breast Cancer Research and Treatment.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.